Pay in 4 interest-free payments of $7.15 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Hypothetical Conservative Combination Protocol A conservative approach to combining these peptides would likely involve: Phase 1: Tirzepatide Establishment (Weeks 1-12) Week 1-4: Tirzepatide 2.5 mg weekly Week 5-8: Tirzepatide 5 mg weekly Week 9-12: Tirzepatide 7.5 mg weekly Cagrilintide: None (establish baseline tolerance) Phase 2: Cagrilintide Introduction (Weeks 13-20) Week 13-16: Tirzepatide 7.5 mg + Cagrilintide 0.6 mg weekly Week 17-20: Tirzepatide 7.5 mg + Cagrilintide 1.2 mg weekly Phase 3: Optimization (Week 21+) Tirzepatide 10-12.5 mg + Cagrilintide 2.4 mg weekly Adjust based on tolerance and response "The key principle when considering any peptide combination is sequential introduction with careful monitoring of tolerability markers, particularly gastrointestinal symptoms that could compound across mechanisms." This theoretical framework prioritizes safety through staged introduction, though actual clinical protocols would require medical supervision and monitoring
Pregnancy or breastfeeding
Aug 2019;22(3):103-110
Your provider then builds your personalized protocol from your unique data
The theoretical synergies described are based on component mechanisms rather than validated combination studies
10.4254/wjh.v12.i5.184 66 KonosicS.PetricevicM.IvancanV.KonosicL.GoluzaE.KrtalicB.et al (2019)
